You are here

Article Text

Article menu
Download PDFPDF
Editorial commentaries
Dopamine agonist withdrawal syndrome (DAWS): perils of flicking the dopamine ‘switch’
  1. Mark J Edwards
  1. Correspondence to Dr Mark J Edwards, Sobell Department, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK; m.j.edwards{at}ucl.ac.uk

https://doi.org/10.1136/jnnp-2012-303570

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Dopamine is a neurotransmitter of such pervasive importance in the central nervous system that it is perhaps not surprising that the effects of its alteration by drugs, disease or both are wide. Parkinson's disease (PD), as James Parkinson himself appreciated,1 is much more than ‘just’ a motor disorder. Likewise, the (side) effects of treatment with dopaminergic drugs are more widespread than their effects on motor function.

    For some years now, a range of addictive and impulsive behaviours have been associated with the use of dopaminergic drugs in the treatment of PD. It is now mandatory for clinicians and specialist nurses caring for patients with PD to counsel patients about these potential side effects prior to prescription of dopaminergic medications, and to regularly enquire about their presence in patients on treatment. Typically, dose …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles